Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Details
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Eligibility
You can join if...
Inclusion Criteria
Must be at least 18 years old at the time of informed consent
Must have confirmed diagnosis of hepatocellular carcinoma
Subjects who are not candidates for ablation, resection, or live transplantation at time of enrollment
Exclusion Criteria
-Prior radiation to the liver or lungs
-Prior liver transplant
-History of other cancer within 5 years of the study